Latest Period
Q4 2025
Security Snapshot
Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share (AURA) Institutional Ownership
CUSIP: 05153U107
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
116
Shares (Excl. Options)
50,234,935
Price
$5.45
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- AURA on Nasdaq
- Shares outstanding
- 62,124,648
- Price per share
- $6.77
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 50,234,935
- Total reported value
- $273,791,080
- % of total 13F portfolios
- 0%
- Share change
- -1,519,014
- Value change
- -$8,935,762
- Number of holders
- 116
- Price from insider filings
- $6.77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AURA - Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 05153U107.
- 116 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 116 to 43 between Q4 2025 and Q1 2026.
- Reported value moved from $273,791,080 to $52,442,092.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 116 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 05153U107?
CUSIP 05153U107 identifies AURA - Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 05153U107:
Significant Owners of Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share (AURA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 11% | $38,214,242 | 6,922,870 | Matrix Capital Management Company LP | 16 May 2025 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.6% | +25% | $30,091,360 | +$10,524,518 | 4,701,775 | +54% | Suvretta Capital Management, LLC | 30 Jun 2025 |
| Frazier Life Sciences Public Fund, L.P. | 6.3% | +26% | $20,523,185 | +$4,675,216 | 4,032,060 | +30% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| BlackRock, Inc. | 5.4% | +10% | $20,617,314 | +$1,842,342 | 3,336,027 | +9.8% | BlackRock, Inc. | 30 Sep 2025 |
| Long Focus Capital Management, LLC | 6.6% | +75% | $18,324,093 | +$4,481,180 | 3,319,582 | +32% | LONG FOCUS CAPITAL MANAGEMENT, LLC | 31 Mar 2025 |
| Advent Life Sciences LLP | 3.3% | $11,768,148 | 2,071,857 | Rajesh Parekh, Ph.D. | 13 Feb 2026 |
As of 31 Dec 2025, 116 institutional investors reported holding 50,234,935 shares of Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share (AURA). This represents 81% of the company’s total 62,124,648 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share (AURA) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 11% | 6,922,870 | 0% | 65% | $37,729,642 |
| Frazier Life Sciences Management, L.P. | 8.2% | 5,100,000 | 0% | 0.75% | $27,795,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.9% | 4,881,125 | 0% | 0.04% | $26,602,131 |
| Long Focus Capital Management, LLC | 7.4% | 4,619,582 | 0% | 1.3% | $25,176,722 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7% | 4,372,884 | 0% | 0.59% | $23,832,218 |
| BlackRock, Inc. | 5.7% | 3,560,424 | +4.5% | 0% | $19,404,310 |
| Medicxi Ventures Management (Jersey) Ltd | 4.9% | 3,039,892 | 0% | 2% | $16,567,411 |
| VANGUARD GROUP INC | 4.7% | 2,936,538 | +1.6% | 0% | $16,004,132 |
| FRANKLIN RESOURCES INC | 3.5% | 2,198,423 | -0.02% | 0% | $11,981,405 |
| Nantahala Capital Management, LLC | 3.4% | 2,117,697 | 0% | 0.69% | $11,541,449 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,255,450 | -0.2% | 0% | $6,845,107 |
| LEVIN CAPITAL STRATEGIES, L.P. | 1.7% | 1,035,586 | -36% | 0.49% | $5,643,944 |
| STATE STREET CORP | 1.5% | 926,534 | +5.4% | 0% | $5,049,610 |
| MILLENNIUM MANAGEMENT LLC | 0.99% | 617,338 | +233% | 0% | $3,364,492 |
| ACORN CAPITAL ADVISORS, LLC | 0.96% | 595,744 | 0% | 1.1% | $3,246,805 |
| B Group, Inc. | 0.92% | 572,576 | 0% | 2.3% | $3,120,539 |
| Regency Capital Management Inc.\DE | 0.87% | 538,584 | -12% | 1.2% | $2,935,283 |
| DIMENSIONAL FUND ADVISORS LP | 0.83% | 517,916 | +4.2% | 0% | $2,822,824 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.71% | 442,789 | -8% | 0% | $2,415,000 |
| NORTHERN TRUST CORP | 0.66% | 412,809 | -4.8% | 0% | $2,249,809 |
| Decheng Capital LLC | 0.58% | 360,483 | -30% | 0.26% | $1,964,632 |
| MORGAN STANLEY | 0.35% | 218,407 | +22% | 0% | $1,190,319 |
| UBS Group AG | 0.28% | 171,639 | -81% | 0% | $935,433 |
| BANK OF AMERICA CORP /DE/ | 0.27% | 165,185 | +357% | 0% | $900,259 |
| RENAISSANCE TECHNOLOGIES LLC | 0.23% | 145,200 | +49% | 0% | $791,340 |
Institutional Holders of Aura Biosciences, Inc. - Common Stock, par value $0.00001 per share (AURA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 7,839,500 | $52,442,092 | +$399,471 | $6.69 | 43 |
| 2025 Q4 | 50,234,935 | $273,791,080 | -$8,935,762 | $5.45 | 116 |
| 2025 Q3 | 51,649,516 | $319,192,259 | +$6,254,107 | $6.18 | 106 |
| 2025 Q2 | 50,616,053 | $316,863,119 | +$67,408,487 | $6.26 | 102 |
| 2025 Q1 | 39,264,901 | $230,096,030 | -$11,860,142 | $5.86 | 91 |
| 2024 Q4 | 39,449,434 | $324,276,778 | +$16,157,250 | $8.22 | 93 |
| 2024 Q3 | 36,866,668 | $329,191,609 | -$25,783,402 | $8.91 | 81 |
| 2024 Q2 | 39,765,227 | $300,437,451 | +$3,314,060 | $7.56 | 75 |
| 2024 Q1 | 39,115,323 | $307,072,789 | +$16,222,241 | $7.85 | 77 |
| 2023 Q4 | 36,998,812 | $327,811,496 | +$89,731,106 | $8.86 | 71 |
| 2023 Q3 | 26,323,010 | $236,119,190 | -$5,574,466 | $8.97 | 62 |
| 2023 Q2 | 27,066,492 | $334,426,517 | +$24,980,886 | $12.35 | 59 |
| 2023 Q1 | 25,069,599 | $232,645,346 | +$10,922,124 | $9.28 | 57 |
| 2022 Q4 | 23,806,818 | $250,037,016 | +$78,469,205 | $10.50 | 49 |
| 2022 Q3 | 16,317,002 | $295,663,462 | +$9,714,465 | $18.12 | 43 |
| 2022 Q2 | 15,793,428 | $223,796,376 | +$29,644,466 | $14.17 | 42 |
| 2022 Q1 | 13,702,730 | $298,756,000 | +$9,092,301 | $22.00 | 34 |
| 2021 Q4 | 13,081,587 | $220,131,000 | +$220,131,000 | $16.98 | 32 |